Search research articles
Contact Us
Filters
Showing results (381-390 of 738) with videos related to
Page
of 74
Sort By:
Neuron
|
January 19, 2024
Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior
Mai-Anh T Vu, Eleanor H Brown, Michelle J Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2023
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
Bradley J Monk, Nicoletta Colombo, Krishnansu S Tewari, et al.
Gynecologic Oncology
|
June 24, 2019
Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients
Katherine C Fuh, James J Java, John K Chan, et al.
The Lancet. Oncology
|
May 12, 2019
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Ignace Vergote, Giovanni Scambia, David M O'Malley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2024
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279
Neil S Horowitz, Wei Deng, Ivy Peterson, et al.
Gynecologic Oncology
|
December 2, 2014
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial
Anne Floquet, Ignace Vergote, Nicoletta Colombo, et al.
JAMA Oncology
|
December 14, 2023
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial
Krishnansu S Tewari, Nicoletta Colombo, Bradley J Monk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2026
Comparing nab-paclitaxel and solvent-based paclitaxel in platinum-resistant ovarian cancer: evidence and perspectives
Jalid Sehouli, Meghan R Forrest, Jolijn D Boer, et al.
The Lancet. Oncology
|
August 7, 2021
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Bradley J Monk, Nicoletta Colombo, Amit M Oza, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 2, 2020
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study
Dana Chase, Helen Q Huang, Bradley J Monk, et al.
Page
of 74
Search research articles
Search
Showing results (381-390 of 738) with videos related to
Sort By:
Page
of 74
Neuron
|
January 19, 2024
Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior
Mai-Anh T Vu, Eleanor H Brown, Michelle J Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2023
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
Bradley J Monk, Nicoletta Colombo, Krishnansu S Tewari, et al.
Gynecologic Oncology
|
June 24, 2019
Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients
Katherine C Fuh, James J Java, John K Chan, et al.
The Lancet. Oncology
|
May 12, 2019
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Ignace Vergote, Giovanni Scambia, David M O'Malley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2024
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279
Neil S Horowitz, Wei Deng, Ivy Peterson, et al.
Gynecologic Oncology
|
December 2, 2014
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial
Anne Floquet, Ignace Vergote, Nicoletta Colombo, et al.
JAMA Oncology
|
December 14, 2023
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial
Krishnansu S Tewari, Nicoletta Colombo, Bradley J Monk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2026
Comparing nab-paclitaxel and solvent-based paclitaxel in platinum-resistant ovarian cancer: evidence and perspectives
Jalid Sehouli, Meghan R Forrest, Jolijn D Boer, et al.
The Lancet. Oncology
|
August 7, 2021
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Bradley J Monk, Nicoletta Colombo, Amit M Oza, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 2, 2020
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study
Dana Chase, Helen Q Huang, Bradley J Monk, et al.
Page
of 74